Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial

REFERENCES

1. 1.↵
   1. Knevel R,
   2. Schoels M,
   3. Huizinga TW,
   4. Aletaha D,
   5. Burmester GR,
   6. Combe B,
   7. et al.

   Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: A systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010;69:987–94.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Smolen JS,
   2. Landewé R,
   3. Breedveld FC,
   4. Dougados M,
   5. Emery P,
   6. Gaujoux-Viala C,
   7. et al.

   EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964–75.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Smolen JS,
   2. Aletaha D,
   3. Grisar J,
   4. Redlich K,
   5. Steiner G,
   6. Wagner O

   . The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: Where are we now? Arthritis Res Ther 2008;10:208.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Aletaha D,
   2. Funovits J,
   3. Keystone EC,
   4. Smolen JS

   . Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007;56:3226–35.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Gulfe A,
   2. Kristensen LE,
   3. Geborek P

   . Six and 12 weeks treatment response predicts continuation of tumor necrosis factor blockade in rheumatoid arthritis: An observational cohort study from southern Sweden. J Rheumatol 2009;36:517–21.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Schiff M,
   2. Keystone E,
   3. Kvien T,
   4. Curtis J,
   5. Emery P,
   6. Luijtens K,
   7. et al.

   DAS28(ESR) response at week 12 is predictive of long-term disease activity in rheumatoid arthritis patients treated with certolizumab pegol. Ann Rheum Dis 2009;68 Suppl 3:543.

   OpenUrl
7. 7.↵
   1. Ichikawa Y,
   2. Saito T,
   3. Yamanaka H,
   4. Akizuki M,
   5. Kondo H,
   6. Kobayashi S,
   7. et al; and
   8. Study Group for the Japanese Ministry of Health, Labor and Welfare. Research for Establishment of Therapeutic Guidelines in Early Rheumatoid Arthritis Program

   . Clinical activity after 12 weeks of treatment with nonbiologics in early rheumatoid arthritis may predict articular destruction 2 years later. J Rheumatol 2010;37:723–9.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Keystone EC,
   2. Curtis JR,
   3. Fleischmann RM,
   4. Furst DE,
   5. Khanna D,
   6. Smolen JS,
   7. et al.

   Rapid improvement in the signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: Post-hoc analysis of a randomized controlled trial. J Rheumatol 2011;38:990–6.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Keystone E,
   2. van der Heijde D,
   3. Mason D Jr.,
   4. Landewé R,
   5. Vollenhoven RV,
   6. Combe B,
   7. et al.

   Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319–29.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Felson DT,
    2. Smolen JS,
    3. Wells G,
    4. Zhang B,
    5. van Tuyl LH,
    6. Funovits J,
    7. et al.

    American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis 2011;70:404–13.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Smolen JS,
    2. Aletaha D,
    3. Bijlsma JW,
    4. Breedveld FC,
    5. Boumpas D,
    6. Burmester G,
    7. et al; and
    8. T2T Expert Committee

    . Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis 2010;69:631–7.

    OpenUrlAbstract/FREE Full Text